IL139960A0 - Macrocylic analogs and methods of their use and preparation - Google Patents

Macrocylic analogs and methods of their use and preparation

Info

Publication number
IL139960A0
IL139960A0 IL13996099A IL13996099A IL139960A0 IL 139960 A0 IL139960 A0 IL 139960A0 IL 13996099 A IL13996099 A IL 13996099A IL 13996099 A IL13996099 A IL 13996099A IL 139960 A0 IL139960 A0 IL 139960A0
Authority
IL
Israel
Prior art keywords
preparation
analogs
macrocylic
methods
useful
Prior art date
Application number
IL13996099A
Other languages
English (en)
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL139960(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of IL139960A0 publication Critical patent/IL139960A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13996099A 1998-06-17 1999-06-16 Macrocylic analogs and methods of their use and preparation IL139960A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (1)

Publication Number Publication Date
IL139960A0 true IL139960A0 (en) 2002-02-10

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13996099A IL139960A0 (en) 1998-06-17 1999-06-16 Macrocylic analogs and methods of their use and preparation

Country Status (24)

Country Link
US (4) US6214865B1 (xx)
EP (4) EP1087960B1 (xx)
JP (1) JP4454151B2 (xx)
KR (1) KR100798600B1 (xx)
CN (1) CN1216051C (xx)
AT (1) ATE502932T1 (xx)
AU (1) AU762998B2 (xx)
BE (1) BE2011C028I2 (xx)
BR (1) BRPI9911326B8 (xx)
CA (3) CA2335300C (xx)
CY (2) CY1111516T1 (xx)
DE (2) DE69943296D1 (xx)
DK (1) DK1087960T3 (xx)
FR (1) FR11C0038I2 (xx)
HK (1) HK1035534A1 (xx)
HU (1) HU227912B1 (xx)
IL (1) IL139960A0 (xx)
LU (1) LU91854I2 (xx)
NO (5) NO328280B1 (xx)
NZ (1) NZ508597A (xx)
PT (1) PT1087960E (xx)
RU (1) RU2245335C2 (xx)
WO (1) WO1999065894A1 (xx)
ZA (1) ZA200007159B (xx)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100798600B1 (ko) 1998-06-17 2008-01-28 에자이 가부시키가이샤 마크로시클릭 유사체 및 그들의 이용 및 제조방법
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
PL219737B1 (pl) 2002-03-22 2015-07-31 Eisai R & D Man Co Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
MXPA05012814A (es) * 2003-05-29 2007-01-25 Abbott Lab Regimen de dosificacion continua con n-(2(2 -((4-hidroxifenil) amino)pirid -3-il)-4- metoxibencen -sulfonamida (abt-751).
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION
CN1993342A (zh) * 2004-06-03 2007-07-04 卫材株式会社 用于制备软海绵素b的中间体
CA2567984C (en) 2004-06-03 2014-05-20 Eisai Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) * 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
CN104311571B (zh) * 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
MX2010010902A (es) * 2008-04-04 2010-12-21 Eisai R&D Man Co Ltd Analogos de halicondrina b.
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
US8765974B2 (en) * 2009-04-14 2014-07-01 Nissan Chemical Industries, Ltd. Method for producing tetrahydropyran compound and intermediate thereof
CN102803254B (zh) * 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
WO2012129100A1 (en) 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
AU2012350420A1 (en) 2011-12-16 2014-07-10 Alphora Research Inc. Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
WO2013097042A1 (en) * 2011-12-29 2013-07-04 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
WO2013142999A1 (en) * 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
RU2689977C2 (ru) 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
AR096238A1 (es) 2013-05-15 2015-12-16 Alphora Res Inc Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
JP6404242B2 (ja) 2013-06-26 2018-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
CN105431438A (zh) * 2013-07-03 2016-03-23 阿方拉研究股份有限公司 用于制备软海绵素b 的大环c1-酮基类似物的合成方法和可用于其中的中间体、包括含有-so2-(对甲苯基)基团的中间体
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
RU2710545C2 (ru) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, пригодные в получении аналогов халихондрина b
MX370611B (es) 2013-12-06 2019-12-18 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
BR112016026545A8 (pt) 2014-05-28 2021-07-06 Eisai R&D Man Co Ltd eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
SG11201706872SA (en) 2015-03-04 2017-09-28 Merck Sharp & Dohme Combination of a pd-1 antagonist and eribulin for treating cancer
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US10308661B2 (en) * 2015-05-07 2019-06-04 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
MX2018009794A (es) * 2016-02-12 2018-12-17 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
JP2019521969A (ja) * 2016-05-26 2019-08-08 ドクター レディズ ラボラトリーズ リミテッド エリブリン及びその中間体の製造方法
MX2018016329A (es) 2016-06-30 2019-09-18 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
WO2018071792A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
WO2018096478A2 (en) 2016-11-23 2018-05-31 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2018124847A1 (ko) 2017-01-02 2018-07-05 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
TWI781163B (zh) 2017-04-05 2022-10-21 哈佛大學校長及研究員協會 巨環化合物及其用途
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
EP3649135B1 (en) 2017-07-06 2022-12-28 President and Fellows of Harvard College Synthesis of halichondrins
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
WO2019093776A1 (ko) 2017-11-09 2019-05-16 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
MX2020006945A (es) 2018-01-03 2020-11-09 Eisai R&D Man Co Ltd Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
US20210260023A1 (en) * 2018-07-20 2021-08-26 Dr. Reddy's Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
JP2022537785A (ja) 2019-06-21 2022-08-29 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ ホモプロパルギルアルコールを調製するための化学酵素的プロセス
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
AU2020380603A1 (en) 2019-11-07 2022-06-02 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
TW202140078A (zh) * 2020-01-22 2021-11-01 大陸商上海森輝醫藥有限公司 艾日布林衍生物的藥物偶聯物、其製備方法及其在醫藥上的應用
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
AU2022316425A1 (en) * 2021-07-22 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Drug conjugate of eribulin derivative
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
KR100798600B1 (ko) * 1998-06-17 2008-01-28 에자이 가부시키가이샤 마크로시클릭 유사체 및 그들의 이용 및 제조방법
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
CA2567984C (en) 2004-06-03 2014-05-20 Eisai Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
CN104311571B (zh) 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
JP5134686B2 (ja) 2007-11-16 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂアナログ合成のための新規な中間体及び前記中間体に用いるための新規な脱スルホニル化反応
MX2010010902A (es) 2008-04-04 2010-12-21 Eisai R&D Man Co Ltd Analogos de halicondrina b.
CN102803254B (zh) 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物

Also Published As

Publication number Publication date
EP1087960A1 (en) 2001-04-04
NO20006316L (no) 2001-02-15
RU2245335C2 (ru) 2005-01-27
CN1312804A (zh) 2001-09-12
EP2277873A1 (en) 2011-01-26
CA2335300A1 (en) 1999-12-23
US6365759B1 (en) 2002-04-02
KR100798600B1 (ko) 2008-01-28
DK1087960T3 (da) 2011-06-14
US6469182B1 (en) 2002-10-22
CY2011010I2 (el) 2014-04-09
NO331183B1 (no) 2011-10-24
PT1087960E (pt) 2011-06-17
AU4573999A (en) 2000-01-05
US8148554B2 (en) 2012-04-03
NO2011026I1 (no) 2012-01-09
CA2755266A1 (en) 1999-12-23
NO20093217L (no) 2001-02-15
AU762998C (en) 2000-01-05
KR20010083050A (ko) 2001-08-31
HU227912B1 (en) 2012-05-29
AU762998B2 (en) 2003-07-10
CA2632433C (en) 2012-02-07
HUP0103357A3 (en) 2002-10-28
EP1087960A4 (en) 2004-12-01
EP1087960B1 (en) 2011-03-23
DE122011100031I1 (de) 2011-12-15
HK1035534A1 (en) 2001-11-30
JP2002518384A (ja) 2002-06-25
WO1999065894A1 (en) 1999-12-23
HUP0103357A2 (hu) 2002-01-28
CA2755266C (en) 2014-08-12
US6214865B1 (en) 2001-04-10
BRPI9911326B8 (pt) 2021-05-25
ZA200007159B (en) 2001-12-04
CN1216051C (zh) 2005-08-24
EP2272839A1 (en) 2011-01-12
NO2011026I2 (no) 2012-06-11
EP2272840A1 (en) 2011-01-12
BE2011C028I2 (en) 2018-08-24
US20110172446A1 (en) 2011-07-14
FR11C0038I1 (fr) 2011-10-14
EP2277873B1 (en) 2012-05-30
BR9911326A (pt) 2001-04-03
EP2272840B1 (en) 2012-08-22
NO2022019I1 (no) 2022-06-03
NO328280B1 (no) 2010-01-25
DE69943296D1 (de) 2011-05-05
CY1111516T1 (el) 2014-04-09
CA2632433A1 (en) 1999-12-23
BR9911326B1 (pt) 2015-01-06
CA2335300C (en) 2008-10-07
LU91854I2 (fr) 2011-10-17
CY2011010I1 (el) 2014-04-09
JP4454151B2 (ja) 2010-04-21
NZ508597A (en) 2004-01-30
FR11C0038I2 (fr) 2013-01-11
EP2272839B1 (en) 2012-08-22
NO20006316D0 (no) 2000-12-12
NO2011018I1 (no) 2011-09-26
ATE502932T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
IL139960A0 (en) Macrocylic analogs and methods of their use and preparation
DE69925133D1 (de) Pyrrolobenzodiazepine
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
IL106673A (en) 7-(substituted)-9- £(substituted glycyl) amido|-6- demethyl-6- deoxytetracyclines
IL106676A0 (en) Novel 7-(substituted)-8-(substituted-9-(substituted glycyl)amido)-6-demethyl-6-deoxytetracyclines
EP0564924A3 (en) 2-oxoethyl derivatives as immunosuppressants
EP0781561A4 (en) NEW MEDICAL USE OF A 5HT 3 ANTAGONIST?
BG103863A (en) Indazolamide compounds as serotoninergic forms
GR850799B (xx)
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
EP1073447A4 (en) N1-MODIFIED GLYCOPEPTIDES
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
NZ229300A (en) Substituted-2-ethenyl-3,4,5,6-tetrahydrothieno (4,3,2-cf)(3)benzazepine derivatives and pharmaceutical compositions
HK1067948A1 (en) Antitumor indolopyprolocarbazole derivative
TW275629B (xx)
EP0412941A3 (en) Phospholipids for the treatment of multiple sclerosis
SI0987268T1 (en) Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXTF Application for patent extension filed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed
PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: ERIBULIN; CORRECTION OF EXTENSION DATE IN GAZETTE APRIL 2015

Extension date: 20230720

EXTG Extension of patent term granted

Extension date: 20230720

KB Patent renewed